- Kessler RC, McGonagle KA, Zhao S et al (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51: 8-19.
- Lepine JP, Gastpar M, Mendlewicz J, Tylee A (1997) Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12: 19-29.
- Katon W, Sullivan MD (1990) Depression and chronic medical illness. J CIin Psychiatry 51: 3-11.
- Mendlewicz J (1998) The broad spectrum of comorbid depression: implications for treatment. Eur Psychiatry 13: 1-8.
- Andrade L, Eaton WW, Chilloat H (1994) Lifetime comorbidity of panic attacks and major depression in a population-based study: symptom profiles. Br J Psychiatry 165: 363-69.
- Baldwin DS, Hawiey CJ, Abed RT et al (1996) A multicentre double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J CUn Psychiatry 57: 46-51
- Montgomery SA (1992) The advantages of paroxetine in different subgroups of depression. Int Clin Psychopharmacd 6 (suppl 4):91-100.
- Ramos PR, de Dios-Vega JL, Cabases JSS et al (1996) Effects of paroxetine in depressed adolescents. Eur J Clin Res & 49-61.
- Bérard R (1998) Adolescent depression: efficacy of paroxetine. Presented at 11th meeting of the European College of Neuropsychopharmacology, Paris, 31 October-4 November.
- Geretsegger C, Bohmer F, Ludwig M (1994) Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioral effects. Int Clin Psychopharmacd 9: 25-29.
- Reynolds CF, 3rd (1994) Treatment of depression in late life. Am J Med 97: 39S-46S.
- Montgomery SA, Dunbar G (1993) Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression.J Clin Psychopharmacd 8: 189-95.
- Feinstein AR (1970) The pre-therapeutic classification of comorbidity in chronic disease. J Chronic Dis 23: 455-68.
- Kaplan MH, Feinstein AR (1974) The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27: 387-404.
- Klein DF (1981) Anxiety reconceptualized. In Anxiety: A new research and changing concepts, (ed DF Klein), 192. Raven Press, New York.
- Lydiard RB (1996) Panic disorder and social phobia: possible implications of comorbid depression for drug therapy. Anxiety 2: 61-70.
- Kessler RC, Stang PE, Wittchen H-U et al (1998) Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry 51: 801-8.
- Kessler RC, Nelson CB, McGonagle KA et al (1996) Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the U.S. National Comorbidity Survey. Br J Psychiatry 168: 8-21.
- Magee WJ, Eaton WW, Wittchen H-U et al (1996) Agoraphobia, simple phobia and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 53: 159-68.
- Den Boer JA (1998) Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. J Clin Psychiatry 59 (suppl 4): 30-6.
- Boyer W (1995) Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a metaanalysis. Int Clin Psychopharmacol 10: 45-9.
- Oehrberg S, Christiansen PE, Behnke K et al (1995) Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 167: 374-9.
- Ballenger JC, Wheadon DE, Steiner M et al (1998) Doubleblind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155: 36-42.
- Lecrubier Y, Bakker A, Dunbar G, Judge R, and the Collaborative Paroxetine Panic Study Investigators (1997) A comparison of paroxetine, clomipramlne and placebo in the treatment of panic disorder. Acta Psychiatr Scand 95: 145-51
- Lecrubier Y, Judge R and the Collaborative Paroxetine Panic Study Investigators (1997) Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand 95: 153-60.
- Judge R, Steiner M. The long-term efficacy and safety of paroxetine in panic disorder (1996) Presented at 20th Collegium International Neurospcyhopharmacology (CINP) Congress, Melbourne, Australia.
- Lydiard RB, Steiner M, Burnham D, Gergel I (1998) Efficacy studies of paroxetine in panic disorder. Psychopharmacol Bull 34: 175-82.
- Weissman MM, Bland RC, Canino GJ et al (1994) The crossnational epidemiology of obsessive compulsive disorder. J Clin Psychiatry 55: 5-10.
- Gorman JM (1996/1997) Comorbid depression and anxiety spectrum disorders. Depres Anxiety 4: 160-8.
- Dominguez RA (1992) Serotonergic antidepressants and their efficacy in obsessive compulsive disorder. J Clin Psychiatry 53 (suppl 10): 56-59.
- Lydiard RB (1994) Obsessive-compulsive disorder: a new perspective in diagnosis and treatment. Int Clin Psychopharmacol 9 (suppl 3): 33-37.
- Wheadon DE, Bushell WD, Steiner M (1993) A fixed-dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive compulsive disorder. Presented at the 32nd Annual Meeting of the American College of Neuropsychopharmacology.
- Zohar J, Judge R (1996) Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 169: 468-74.
- McTavish D, Benfield P (1990) Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 39: 136-53.
- Steiner M (1995) Long-term treatment and prevention of relapse in OCD with paroxetine. Presented at the Annual Meeting of the American Psychiatry Association, Miami.
- Lepine JP, Lellouch J (1990) Classification and epidemiology of social phobia. Ew Arch Clin Neurosci 244: 290-96.
- Davidson JR, Hughes DL, George LK, Blazer DG (1993) The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psycho! Med 23: 709 -18.
- Stein MB, Liebowitz MR, Lydiard RB et al (1998) Paroxetine treatment of generalised social phobia (social anxiety disorder). A randomised controlled trial. JAMA 280: 708-13.
- Baldwin D, Bobes J, Stein DJ et al (1999) Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 175: 120-26.
- Feldman E, Mayou R, Hawton K, Smith EB (1987) Psychiatric disorder in medical inpatients. QJ Med 63: 405-12.
- Schleifer SJ, Macarl-Hinson MM, Coyle DA et al (1989) The nature and course of depression following myocardial infarction. Arch Intern Med 149: 1785-89.
- Carney RM, Rich, MW, Freedand KE et al (1988) Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 50: 627-33.
- Dalack GW, Roose SP (1990) Perspectives on the relationship between cardiovascular disease and affective disorder. J Clin Psychiatry 51: 4-9.
- Fielding R (1991) Depression and acute myocardial infarction: A review and reinterpretation. Soc Sci Med 32: 1017-27.
- Glassman AH (1993) Risks of antidepressants in the elderly. Tricyclic antidepressants and arrhythmias -- revising risks. Presented at Sixth Annual Meeting of the International Psychiatric Association (IPA), Berlin.
- Davenport J (1988) Cardiovascular effects of antidepressants. Avoiding cardiotoxicity in the elderly. Postgraduate Medicine 84: 105-15.
- Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) Preliminary report· Effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406-12.
- Rechlin T, Weis M, Claus D (1994) Heart rate variability in depressed patients and differential effects of paroxetine and amitriptyline on cardiovascular autonomie functions. Pharmacopsychiatry 27: 124-28.
- Rechlin T (1994) The effect of amitriptyline, doxepin, fhioxamine, and paroxetine treatment on heart rate variability. J Gin Psychopharmacol 14: 392-95.
- Roose SP, Laghrissi-Thode F, Kennedy JS et al (1998) Comparison of paroxetine and nortriptyüne in depressed patients with ischaemic heart disease. JAMA 279: 287-91.
- Katz PP, Yelin EH (1993) Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rhewnatol 20: 790-96.
- Parker JC, Wright GE (1995) The implications of depression for pain and disability in rheumatoid arthritis. Arthritis Care Res 8: 279-83.
- Bryson HM, Wilde MI (1996) Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging 8: 459-76.
- Egbunike IG, Chaffee BJ (1990) Antidepressants in the management of chronic pain syndromes. Pharmacotherapy 10: 262-70.
- Frank RG, Kashani JH, Parker JC et al (1988) Antidepressant analgesia in rheumatoid arthritis. J Rheumatol 15: 1632-38.
- Jung AC, Staiger T, Sullivan M (1997) The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med 12: 384-89.
- Hunter B (1997) Depression associated with rheumatoid arthritis - comparison of paroxetine and amitriptyline. Poster presented at the 10th Congress of the European College of Neuropsychopharmacology, Vienna.
- Aragona M, Muscatello MR, Mesiti M (1997) Depressive mood disorders in patients with operable breast cancer. J Exp Clin Cancer Res 16: 111-18.
- Finder KL, Ramfrez AJ, Black ME et al (1993) Psychiatric disorder in patients with advanced breast cancer prevalence and associated factors. Eur J Cancer 29A: 524-27.
- Contu A (1997) Depression in breast cancer patients - comparison of paroxetine and amitriptyline. Poster presented at the 10th Congress of the European College of Neuropsychopharmacology, Vienna.
- Cummings JL (1992) Depression and Parkinson's disease: a review. Am J Psychiatry 149: 443-54.
- Mayberg HS, Solomon DH (1995) Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neural 65: 49-60.
- Richard IH, Kurlan R and the Parkinson Study Group (1997) A survey of antidepressant drug use in Parkinson's disease. Neurology 49: 1168-70.
- Richard IH, Kurlan R, Tanner C (1997) Serotonin syndrome and the combined use of deprenyl and antidepressant in Parkinson's disease (Parkinson Study Group). Neurology 48: 1070-77.
- Weiss DM (1995) Serotonin syndrome in Parkinson disease. J Am Board Family Practice 8: 400-2.
- Toyama SC, Iacono RP (1994) Is it safe to combine a selective serotonin reuptake inhibitor with selegilline? Ann Pharmacother 28: 405-6.
- Katona CLE, Hunter BN, Bray J (1998) A double-blind comparison of the efficacy and safety of paroxetine and irmpramine in the treatment of depression with dementia. Int J Geriatric Psychiatry 13: 100-8.
- Gunasekara NS, Noble S, Benfield P (1998) Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 55: 85-120.
- Brosen K, Hansen JG, Nielsen KK et al (1993) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Pharmacol 44: 349-55.
- Haenen J (1991) An interaction study of paroxetine on lithium plasma levels in depressed patients stabilized on lithium therapy. Presented at the 5th World Congress of Biological Psychiatry, Florence.
- Tulloch IF, Johnson AM (1992) The pharmacologie profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry 53 (suppl 2): 7-12.
- Cooper SM, Jackson D, Loudon JM et al (1989) The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam or alcohol. Acta Psychiatr Scand 80 (suppl 350): 53-5.
- Marley E, Wozniak KM (1983) Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors. Psychol Med 13: 735-49.
- Marley E, Wozniak KM (1984) Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5hydroxytryptamine, dopamine, or noradrenahne re-uptake. J Psychiatr Res 18: 173-89.
- Bannister SJ, Houser VP, Hulse JD et al (1989) Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand 80 (suppl 350): 102-6.
- Skop BP, Finkelstein JA, Mareth TR et al (1994) The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med 12: 642-44.
- Grunhaus L, Pande AC, Brown MB, Greden JF (1994) Clinical characteristics of patients with concurrent major depressive disorder and panic disorder. Am J Psychiatry 151: 541-6.
- Lecrubier Y, Ustun TB (1998) Panic and depression: aworldwide primary care perspective. Int Clin Psychopharmacol 13 (suppl 4): S7-S11.
- Reich J, Warshaw M, Peterson LG et al (1993) Comorbidity of panic and major depressive disorder. J Psychiatr Res 27: 23-33.
- Coulehan JL, Schulberg HC, Block MR et al (1990) Medical comorbidity of major depressive disorder in a primary medical practice. Arch Intern Med 150: 2363-67.
- Isaac M (1999) Where are we going with SSRIs? Eur Neuropsychapharmacol 9 (suppl 3): S101-S106.
- Nelson JC, Kennedy JS, Pollack BG et al (1999) Treatment of major depression with nortriptytine and paroxetine in patients with ischemie heart disease. Am J Psychiatry 156: 1024-28.
- Roose SP, Spatz E (1999) Treatment of depression in patients with heart disease. J Clin Psychiatry 60 (suppl 20): 34-37.
International Journal of Psychiatry in Clinical Practice
Volume 5, 2001 - Issue 1